Bezlotoxumab

BreastfeedingPediatric
  • TRADE NAME: Zinplava (Merck)
  • INDICATIONS: To reduce the recurrence of Clostridium difficile infection (CDI) in patients who are receiving antibacterial treatment of CDI and are at high risk for CDI recurrence
  • CLASS: C. difficile toxin inhibitor, Monoclonal antibody
  • HALF-LIFE: ~19 days

FDA APPROVAL DATE: 10/24/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
No data available

Our database has 8 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top